Brigatinib CAS 1197953-54-0 Raw Materials Powder

Related Attributes

Product details

Brigatinib Powder Usage and Synthesis.

Brigatinib Powder is a next-generation tyrosine kinase inhibitor with significant efficacy in ALK+ metastatic NSCLC,

Brigatinib CAS 1197953-54-0 for the treatment of mesenchymal lymphoma kinase (ALK)-positive non-small cell lung cancer  and in patients whose disease has progressed after crizotinib (Crizotinib) therapy or is not On August 30, 2016,  the FDA granted brigatinib breakthrough therapy and rare drug status for the treatment of ALK+NSCLC to patients whose  first-generation ALK+NSCLC treatment, crizotinib, has progressed or is not tolerated,  granting priority review of the marketing application and allowing for a rolling submission of the application  materials.

The FDA approved Brigatinib Raw Materials on April 28,  2017 Brigatinib Raw Materials to market under the trade name Alunbrigtm.

Application/Function of Brigatinib Powder.

Brigatinib Powder is a tyrosine kinase receptor (MERTK) inhibitor that can be used in combination with epidermal growth factor receptor (EGFR) inhibitors for cancer treatment.

Brigatinib Raw Materials are tyrosine kinase inhibitors. Bugtinib is indicated for patients with AlK-positive metastatic NSCLC who cannot tolerate crizotinib treatment or whose disease has progressed. This indication is approved on an accelerated basis based on tumor response rate and duration of response, and subsequent approval of the indication may depend on confirmation of further clinical trials and description of clinical benefit.

Brigatinib (AP26113) is a potent and selective ALK inhibitor with IC50=0.6 nM; Also a ROS1 inhibitor, IC50=0.9 nM. It also inhibits IGF-1R, FLT3, FLT3(D835Y), and EGFR with relatively low potency.

Why choose us?

HRK Factory

About Shipping